deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT02576574

Avelumab in First-line NSCLC (JAVELIN Lung 100)

A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC

Sponsor: EMD Serono Research & Development Institute, Inc.

Conditions First Line Non-Small Cell Lung Cancer
Interventions Avelumab Avelumab Weekly Carboplatin Cisplatin Gemcitabine Paclitaxel Pemetrexed
Updated 42 times since 2017 Last updated: Jan 20, 2025 Started: Oct 29, 2015 Primary completion: Dec 6, 2021 Completion: Jan 29, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates First Line Non-Small Cell Lung Cancer and is currently completed. EMD Serono Research & Development Institute, Inc. leads this study, which shows 42 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~May 2019 · 4 months · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshot~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Feb 2023 · 8 months · monthly snapshot~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Apr 2024 · 4 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot

Change History

42 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Present [monthly]

    Completed PHASE3

  3. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

▶ Show 37 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Dec 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Mar 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  8. Jan 2022 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

  9. Nov 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  10. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE3

  11. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  12. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE3

  13. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  14. Jul 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  15. Apr 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  16. Jan 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  17. Nov 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

  18. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  19. Jul 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  20. May 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  21. Jan 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  22. Nov 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  23. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  24. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  25. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  26. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  27. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  28. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  29. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  30. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  31. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  32. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  33. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  34. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  35. Mar 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  36. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  37. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • EMD Serono Research & Development Institute, Inc.
  • Merck KGaA, Darmstadt, Germany
Data source: EMD Serono

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Alberton, South Africa , Albury, Australia , Almada, Portugal , Amadora-Lisbon, Portugal , Angers, France , Ankara, Turkey (Türkiye) , Antalya, Turkey (Türkiye) , Antwerp, Belgium , Arkhangelsk, Russia and 252 more locations